ライフサイエンスコーパス: bisphosphonate

1 ly treated with ibandronate, a commonly used bisphosphonate.

2 uires aggressive intravenous hydration and a bisphosphonate.

3 enhanced by covalent functionalization with bisphosphonate.

4 te, and data are extremely limited for other bisphosphonates.

5 e to AFFs in patients treated with long-term bisphosphonates.

6 calcium channel blockers, beta-blockers, and bisphosphonates.

7 We did not have information on intravenous bisphosphonates.

8 ine T-scores of less than -2.0 also received bisphosphonates.

9 ab may delay worsening of pain compared with bisphosphonates.

10 mperfecta are often treated with intravenous bisphosphonates.

11 a potential adjuvant benefit of intravenous bisphosphonates.

12 , hormone therapy, and the administration of bisphosphonates.

13 patients were stratified based on the use of bisphosphonates.

14 has osteopenia, should she be treated with a bisphosphonate?

15 no evidence of benefit from the addition of bisphosphonates (1.03 [0.89-1.18]; p=0.724) or zoledroni

16 The PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase) enzyme has a pivotal role in th

17 ith parathyroidectomy (4.2% at <2 years) and bisphosphonates (3.6% at <2 years) and declined progress

18 methyl 2-(thiazole-2-ylamino)ethylidene-1,1- bisphosphonate (7), specifically expanded gammadelta T c

19 mice are also enhanced on administration of bisphosphonate, a class of drugs frequently used for the

20 r high-dose therapy with nitrogen-containing bisphosphonates, a RANKL inhibitor, antiangiogenic agent

21 scuss these considerations in the context of bisphosphonate active comparator initiation and disconti

22 Bisphosphonates after KT were more frequently used in gr

23 Denosumab is a novel alternative to bisphosphonates against myeloma bone disease.

24 ion was inhibited pharmacologically with the bisphosphonate alendronate.

25 integrin alpha4beta1 on the MSC surface to a bisphosphonate (alendronate, Ale) that has a high affini

26 Bisphosphonates also had no impact on survival or freedo

27 We describe the synthesis of PP-IP bisphosphonate analogues (PCP-IPs), which are resistant

28 Acyclic nucleoside bisphosphonates (ANbPs) have previously been shown to be

29 ed drugs, known as C3 and C6, of an inactive bisphosphonate and a bone activating synthetic prostagla

30 Conjugates incorporating a bisphosphonate and an antibiotic for bone-targeted deliv

31 model, we assessed the effect of established bisphosphonate and anti-RANKL therapies on bone metastas

32 ct on tooth-extraction wound healing between bisphosphonate and PTH therapies.

33 Both bisphosphonates and denosumab improve BMD in men with no

34 Both bisphosphonates and denosumab, through different pathway

35 aluated the relationship between use of oral bisphosphonates and endometrial cancer risk in a cohort

36 sk of oesophageal cancer in women prescribed bisphosphonates and is based on the largest number of ex

37 To make recommendations regarding the use of bisphosphonates and other bone-modifying agents as adjuv

38 ciation between atypical femur fractures and bisphosphonates and other risk factors.

39 Although bisphosphonates and tetracyclines were capable of locali

40 The affinity between bisphosphonates and the apatite structure of bone metast

41 Although bisphosphonates and tumor necrosis factor-alpha inhibito

42 50 years of age or older who were receiving bisphosphonates and who were enrolled in the Kaiser Perm

43 sphonates, post-treatment residual effect of bisphosphonates, and a potential adjuvant benefit of int

44 nations of potassium citrate, thiazides, and bisphosphonates, and correcting bone and urinary abnorma

45 is rare but serious potential side effect of bisphosphonates, and have bisphosphonate-related orbital

46 fects of anti-resorptive drugs, particularly bisphosphonates, and the absence of clear evidence in su

47 ncreased in frequency with the advent of new bisphosphonates, antitumor necrosis factor biologic agen

48 target bone without requiring a traditional bisphosphonate are synthesized.

49 Bisphosphonates are a common treatment to reduce osteopo

50 Continuous users of oral bisphosphonates are at a higher risk of developing wet A

51 Bisphosphonates are common medications used for the trea

52 hip, nonvertebral, and vertebral fractures; bisphosphonates are commonly used as first-line treatmen

53 Linear 2-alkylaminoethyl-1,1-bisphosphonates are effective agents against proliferati

54 Bisphosphonates are effective in reducing hip and osteop

55 Bisphosphonates are inhibitors of geranylgeranyl diphosp

56 Isoprenoid-substituted bisphosphonates are known to serve as inhibitors of the

57 Bisphosphonates are routinely used in the treatment of m

58 Bisphosphonates are the frontline therapy for osteoporos

59 Bisphosphonates are the most widely prescribed pharmacol

60 Bisphosphonates are therapeutic agents in the treatment

61 Bisphosphonates are thought to act through the osteoclas

62 Bisphosphonates are used for the treatment of bone metas

63 erial such as platelet rich fibrin (PRF) and bisphosphonates as alendronate (ALN).

64 CCL3, beta-catenin inhibitors, anti-RANKL or bisphosphonates as potential combination therapy for PAR

65 antiresorptive agents such as denosumab and bisphosphonates, as well as complementary approaches suc

66 ears, 149 hip fractures were prevented and 2 bisphosphonate-associated atypical fractures occurred in

67 Bisphosphonate-associated osteonecrosis of the jaw (BRON

68 Bisphosphonate binding depends on coordination by Mg(2+)

69 rdination by Mg(2+) ions, but various Mg(2+)-bisphosphonate-binding stoichiometries were previously r

70 Moreover, various metal-bisphosphonate-binding stoichiometries were previously r

71 The traditional bisphosphonate (BP) alendronate (Aln) or IG9402, a BP an

72 The average number of bisphosphonate (BP) infusions was significantly higher i

73 The association between oral bisphosphonate (BP) intake and colorectal cancer (CRC) r

74 Purpose To assess whether bisphosphonate (BP) use is associated with decreased bre

75 Bisphosphonate (BP)-related osteonecrosis of the jaw (BR

76 orpholinamide CHCl (6a, 6b) and CHF (7a, 7b) bisphosphonates (BPs) equipped with an (R)-mandelic acid

77 Data on the effect of oral bisphosphonates (BPs) on risk of upper gastrointestinal

78 Bisphosphonates (BPs) should be considered in all patien

79 Most available GGPPS inhibitors are bisphosphonates, but the clinically available compounds

80 l fractures and initiation of treatment with bisphosphonates, calcitonin, or raloxifene were treated

81 Because bisphosphonates can cause adverse side effects and are c

82 Bisphosphonates can mimic the pyrophosphate leaving grou

83 Adjuvant use of bisphosphonates can reduce the incidence of bone metasta

84 Here we describe a novel osteoadsorptive bisphosphonate-ciprofloxacin conjugate (BV600022), utili

85 302.5 events per 1000 patients treated with bisphosphonates compared with 206.1 events per 1000 pati

86 d 85.5 events per 1000 patients treated with bisphosphonates compared with 55.9 events per 1000 patie

87 riethylene glycol to form triethylene glycol-bisphosphonate conjugates 4 and 5 as model compounds for

88 via Mg(2+) to the same site as seen in other bisphosphonate-containing structures.

89 After 3 to 5 years of treatment, bisphosphonate continuation versus discontinuation reduc

90 Osteoclast inhibitors such as bisphosphonates delay SREs but do not prevent skeletal c

91 Systemic bisphosphonate delivery led to increased peri-implant bo

92 d different implant materials under systemic bisphosphonate delivery using micro-computed tomography

93 undergoing oral surgery while medicated with bisphosphonate, denosumab or anti-angiogenic agents.

94 There is high-strength evidence that bisphosphonates, denosumab, and teriparatide reduce frac

95 We hypothesized that a bisphosphonate derivative of enoxacin, bis-enoxacin (BE)

96 p strength compared to no treatment, whereas bisphosphonate did not.

97 Bisphosphonate discontinuation was associated with a rap

98 sphosphonate use and rapidly decreased after bisphosphonate discontinuation.

99 Thus, bisphosphonate drastically inhibited bone remodeling.

100 the great potential for non-invasive in vivo bisphosphonate drug tracking.

101 osteocytes treated with alendronate (AD), a bisphosphonate drug, inhibited the migration of human br

102 lytic bone diseases, the currently available bisphosphonate drugs exhibit poor cellular uptake and di

103 inhibition of hFPPS and the discovery of non-bisphosphonate drugs for potentially treating nonskeleta

104 ome barriers to cell penetration of existing bisphosphonate drugs in this and other systems by simple

105 The treatment of bisphosphonate drugs, either alendronate (ALN) or zoledr

106 mammalian isoprenoids and the key target of bisphosphonate drugs.

107 Introduction of bisphosphonates during the past 20 years has targeted bo

108 Pivoxil bisphosphonate esters enter cells where esterases conver

109 The bisphosphonate esters stimulated gammadelta T cells to s

110 mined that the administration of PPi and the bisphosphonate etidronate to Abcc6(-/-) mice fully inhib

111 enopausal osteoporosis who had taken an oral bisphosphonate for at least 3 years before screening and

112 ocetaxel or standard of care with or without bisphosphonates for men with high-risk localised or meta

113 Of 17 trials of bisphosphonates for men with M0 disease, survival result

114 ven eligible randomised controlled trials of bisphosphonates for men with M1 disease.

115 ng followed by selective treatment with oral bisphosphonates for those diagnosed with osteoporosis is

116 One-time BMD screening followed by oral bisphosphonates for those with osteoporosis or osteopeni

117 In the reaction, the bisphosphonate functional groups -C(PO(3)H(2))(2)(OH) in

118 Bisphosphonates (generic) and denosumab reduce the risk

119 We reported a series of triazole bisphosphonate GGDPS inhibitors, of which the most poten

120 ndronate (ALN), an influential member of the bisphosphonate group, is known to enhance osteoblastogen

121 Alendronate (ALN), a member of the amino-bisphosphonate group, is known to enhance periodontal ti

122 Ps conjugated with alendronate (ALD), of the bisphosphonate group.

123 phorus dendrimers bearing 48 (G3) or 96 (G4) bisphosphonate groups on their surface.

124 howed that tissue from patients treated with bisphosphonates had deficits in fracture toughness, with

125 of wild-type human GGPPS (hGGPPS) bound to a bisphosphonate has not been resolved.

126 Use of oral bisphosphonates has been associated with a decreased ris

127 The combining of anabolic agents with bisphosphonates has not improved efficacy.

128 ixture of homogeranyl and homoneryl triazole bisphosphonates has previously demonstrated potent activ

129 y believed to be exclusively associated with bisphosphonates, has been implicated in recent reports w

130 treatments for osteoporosis, except for the bisphosphonates, has dampened enthusiasm for this approa

131 Bisphosphonates have a widespread indication for osteopo

132 Bisphosphonates have been suggested to slow this progres

133 Bisphosphonates have been used to treat Duchenne muscula

134 Bisphosphonates have benefits in breast cancer and multi

135 ture rates that followed the introduction of bisphosphonates have now levelled off, which is coincide

136 Bisphosphonates improve pain in patients with bony metas

137 0 [88%] of 3109 men) showed that addition of bisphosphonates improved survival (0.88 [0.79-0.98]; p=0

138 ith recombinant human IGF-1 in one study and bisphosphonates in another--increased BMD, but not to th

139 The role of adjuvant bisphosphonates in early breast cancer is uncertain.

140 justed OR for wet AMD among regular users of bisphosphonates in the 1, 2, and 3 years prior to the in

141 Randomized trials have studied bisphosphonates in the adjuvant setting of early breast

142 ate, an orally administered third-generation bisphosphonate, in children with the disease.

143 Long-term bisphosphonates increased risk for 2 rare harms: atypica

144 m concentration in animals pretreated with a bisphosphonate, indicating that the increase did not res

145 at alendronate, a member of the N-containing bisphosphonates, indirectly inhibits osteoblast function

146 report a case of orbital inflammation after bisphosphonate infusion in a patient who was already rec

147 risk of ocular inflammatory side effects of bisphosphonate infusions and the need for referral to an

148 Bisphosphonates inhibit osteoclast differentiation/funct

149 At approximately 100% efficacy, bisphosphonates inhibited cancer progression while, in c

150 ted from MLO-Y4 osteocyte cells treated with bisphosphonates inhibited the anchorage-independent grow

151 mediates, 3- to 4-fold, upstream of DMADP in bisphosphonate-inhibited leaves, but the DMADP pool was

152 A bisphosphonate inhibitor binds to the same site.

153 mpared with approximately 0.5 microM for the bisphosphonate inhibitor, zoledronate).

154 We used bisphosphonate inhibitors, alendronate and zoledronate,

155 Bisphosphonate injections in Ank (+/+) mice replicate th

156 Here, we apply specific bisphosphonate interactions with the positively charged

157 lth Initiative (WHI), have found that use of bisphosphonates is associated with reduced risk of devel

158 Zoledronic acid, a potent bisphosphonate, is commonly administered to patients wit

159 Though the disease is managed using bisphosphonate, it eventually leads to total hip replace

160 alogous Co(II)2 complex with a CEST-inactive bisphosphonate ligand exhibits no such pH response, conf

161 Functionalization with a bisphosphonate ligand results in significant binding to

162 tra(carboxamide) and/or hydroxyl-substituted bisphosphonate ligands.

163 However, bisphosphonates may oversuppress remodelling resulting i

164 Bisphosphonates may prevent or treat bone loss in such p

165 Bisphosphonates may prevent or treat the bone loss promo

166 Evidence showed that bisphosphonates may slow loss of BMD among transplant re

167 Because of bisphosphonate medication, dental implantation with a su

168 Findings of NSABP B-34 suggest that bisphosphonates might have anticancer benefits for older

169 yield synthesis of a novel, small molecule, bisphosphonate-modified trans-cyclooctene (TCO-BP, 2) th

170 Nitrogen-containing bisphosphonates (N-BP), including zoledronic acid (ZOL)

171 flection at osteonal boundaries than that of bisphosphonate-naive patients.

172 Nitrogen-containing bisphosphonates (NBPs) are taken by millions for bone di

173 Here we report the self-assembly of zinc bisphosphonate NCPs that carry 48 +/- 3 wt% cisplatin pr

174 have now explored the potential efficacy of bisphosphonates, nonhydrolyzable PPi analogs, in prevent

175 val and overall survival (OS), making it the bisphosphonate of choice for newly diagnosed myeloma pat

176 ratios (HRs) of the effects of docetaxel or bisphosphonates on survival (time from randomisation unt

177 study was aimed at examining the effects of bisphosphonates on the risk of endometrial cancer.

178 oth extractions are typically on either oral bisphosphonate or parathyroid hormone (PTH) therapy.

179 as compared to patients treated either with bisphosphonates or calcium and vitamin D.

180 When a pharmacologic agent is indicated, bisphosphonates or denosumab at osteoporosis-indicated d

181 ourable for up to 10 years of treatment with bisphosphonates or denosumab.

182 acid) (PLGA), polyethylene glycol (PEG), and bisphosphonate (or alendronate, a targeting ligand).

183 per 0.1 increment; p = 0.007) and the use of bisphosphonates (OR: 3.57, 95% CI: 1.14 to 10.80 p = 0.0

184 categories including hormonal, chemotherapy, bisphosphonates, or immunotherapy).

185 ivery of a metabolically resistant methylene bisphosphonate (PCP) analog of InsP(8); PCP analogs of o

186 age at the initiation of AI therapy, type of bisphosphonates, post-treatment residual effect of bisph

187 Antiresorptive treatments such as bisphosphonates prevent and counteract these side-effect

188 Bisphosphonates prevent skeletal-related events in patie

189 Using a similar approach, we synthesized bisphosphonate prodrugs and found that they efficiently

190 Therefore, bisphosphonate prodrugs could enhance the effectiveness

191 le peptide-linked conjugate for targeting of bisphosphonate prodrugs to bone and slow release liberat

192 ting the involvement of three Mg(2+) ions in bisphosphonate-protein interactions.

193 ly elaborated to the pyrido[2,3-d]pyrimidine bisphosphonates (PYPY-BPs).

194 ial side effect of bisphosphonates, and have bisphosphonate-related orbital inflammation on their dif

195 cid, the most frequent agent associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ),

196 uggest that periodontitis is associated with bisphosphonate-related osteonecrosis of the jaw (BRONJ).

197 ed isoflavones in various proportions) and a bisphosphonate (risedronate).

198 orosis, diagnosed in 2004, she received oral Bisphosphonates (Risedronate) from 2004 until 2007 follo

199 Treatment with multiple statins, bisphosphonates, squalene synthase inhibitors, and small

200 alities for PXE, including administration of bisphosphonates, stable PPi analogs with antimineralizat

201 Present bisphosphonates stimulate gammadelta T cells but were de

202 )](2+)* followed by (1)O(2) oxidation of the bisphosphonate substituent.

203 Radiolabeled bisphosphonates such as (99m)Tc-3,3-diphosphono-1,2-prop

204 Nitrogen-bisphosphonates such as zoledronic acid (ZOL) trigger se

205 is common practice in patients treated with bisphosphonates, such as those who fracture while on the

206 Bisphosphonates suffer from poor "drug-like" properties

207 efits and harms of osteoporosis medications (bisphosphonates, teriparatide, raloxifene, and denosumab

208 an be used to monitor the effect of stopping bisphosphonate therapy (eg, to identify a threshold abov

209 Bisphosphonate therapy and rank-ligand monoclonal antibo

210 Bisphosphonate therapy has been shown to reduce fracture

211 Bisphosphonate therapy has been shown to reduce fracture

212 the jaw after suspended oral and intravenous Bisphosphonate therapy implicating that the biologic the

213 ineral density (BMD) screening and selective bisphosphonate therapy in women with osteoporosis or ost

214 teopenia; annual BMD screening and selective bisphosphonate therapy in women with osteoporosis or ost

215 These findings suggest that bisphosphonate therapy is effective at reducing perforat

216 Oral bisphosphonate therapy was started if DXA hip T scores w

217 included: autoimmune disease, heavy smoking, bisphosphonate therapy, implant location, diameter and d

218 stmenopausal osteoporosis transitioning from bisphosphonate therapy.

219 here were 198 cases of wet AMD on continuous bisphosphonate therapy.

220 ubstantial benefit for patients who received bisphosphonate therapy.

221 e of a reduction in risk of a DFS event with bisphosphonate therapy.

222 y posttransplant may influence the impact of bisphosphonate therapy.

223 th osteoporosis or osteopenia; and universal bisphosphonate therapy.

224 A new series of thienopyrimidine-based bisphosphonates (ThP-BPs) were identified that inhibit h

225 e no studies evaluating the influence of the bisphosphonate tiludronic acid (TIL) on periodontitis.

226 nic acid polymers derivatised with a pendant bisphosphonate to generate hydrogels with enhanced mecha

227 treatment options can be used, ranging from bisphosphonates to denosumab, as well as teriparatide.

228 linicians offer pharmacologic treatment with bisphosphonates to reduce the risk for vertebral fractur

229 istic repurposing of existing compounds (eg, bisphosphonates) to one driven by advances in fundamenta

230 Furthermore, bisphosphonate-treated bone demonstrated reduced tensile

231 of young, treatment-naive osteoporosis, and bisphosphonate-treated cases were investigated in femora

232 Bisphosphonate-treated exhibited the lowest properties.

233 untreated fracture patients (Fx-Untreated); bisphosphonate-treated fracture patients (Fx-BisTreated)

234 Bone from bisphosphonate-treated fracture patients exhibited fewer

235 mechanical properties of bone biopsies from bisphosphonate-treated patients with AFFs to those from

236 and nanoindentation showed that tissue from bisphosphonate-treated women with atypical fractures was

237 s harder and more mineralized than that from bisphosphonate-treated women with typical osteoporotic f

238 based on fracture morphology and history of bisphosphonate treatment [+BIS Atypical: n = 12, BIS dur

239 Previous bisphosphonate treatment attenuates the bone-forming eff

240 Collectively, these results suggest that bisphosphonate treatment may be beneficial by a dual eff

241 ructural and mechanical properties following bisphosphonate treatment may foster resistance to fractu

242 he unusual fracture morphology suggests that bisphosphonate treatment may impair toughening mechanism

243 Long-term bisphosphonate treatment may increase risk for rare adve

244 This paper aims to investigate the effect of bisphosphonate treatment on microstructure and mechanica

245 s associated with reduced fracture risk, and bisphosphonate treatment was not superior to observation

246 In combined fosmidomycin/bisphosphonate treatment, pathway intermediates accumula

247 of ovariectomized mice, which was blocked by bisphosphonate treatment.

248 ical osteoporotic fractures with and without bisphosphonate treatment.

249 in the risk of hip and other fractures with bisphosphonate treatment.

250 We found that bisphosphonate treatments significantly reduced minerali

251 nconsistent for formal meta-analyses for the bisphosphonate trials.

252 As an example, bisphosphonate trimethyl ester 3a and P,P'-dimethyl este

253 ncology Group performance status (0-1 vs 2), bisphosphonate use (yes vs no), and urinary N-telopeptid

254 study showed an inverse association between bisphosphonate use and colorectal cancer.

255 r fracture increased with longer duration of bisphosphonate use and rapidly decreased after bisphosph

256 MSMs and SNAFTMs to account for time-varying bisphosphonate use did not alter conclusions in this exa

257 ic and hip fractures during 1 to 10 years of bisphosphonate use far outweighed the increased risk of

258 pheral fractures, clinicians should consider bisphosphonate use in patients at high fracture risk who

259 Additional adjustment for vitamin D and bisphosphonate use in the previous month reduced the haz

260 As an example, we explore the effect of bisphosphonate use on disease-free survival (DFS) using

261 fit profile was modeled for 1 to 10 years of bisphosphonate use to compare associated atypical fractu

262 itamin D use and time-varying confounding by bisphosphonate use using 1) marginal structural models (

263 The rate ratio for wet AMD for continuous bisphosphonate use was 1.99 (95% CI: 1.41-2.79).

264 lth interview was conducted at baseline, and bisphosphonate use was ascertained from an inventory of

265 In conclusion, we found that oral bisphosphonate use was associated with a decreased odds

266 prospective cohort of postmenopausal women, bisphosphonate use was associated with a statistically s

267 The sensitivity and PPV for bisphosphonate use were both 80% (95% confidence interva

268 have contributed to substantially decreased bisphosphonate use, and the incidence of hip fractures m

269 otal alkaline phosphatase level, and current bisphosphonate use, then randomly assigned (2:1) to rece

270 Data on risk factors, including bisphosphonate use, were obtained from electronic health

271 baseline pain, extraskeletal metastases, and bisphosphonate use, were randomly assigned in a 1:1 rati

272 there is a newly recognized adverse event of bisphosphonate use: atypical subtrochanteric femur fract

273 l fracture increased with longer duration of bisphosphonate use: the hazard ratio as compared with le

274 Bisphosphonates used for treatment inhibit bone resorpti

275 ation of antiresorptive medications, such as bisphosphonates, used in the treatment of bone malignanc

276 esophageal and gastric cancer development in bisphosphonate users compared to non-users.

277 lated covariates and use of corticosteroids, bisphosphonates, vitamin D and calcium supplements (OR,

278 age-adjusted HR for women who regularly used bisphosphonates was 0.92 (95% CI, 0.73 to 1.14) and was

279 Ever use of bisphosphonates was associated with reduced endometrial

280 stronger inverse association for ever use of bisphosphonates was observed for men (OR 0.63; 95% CI: 0

281 ductoisomerase, alone or in combination with bisphosphonates was used to inhibit carbon input into DX

282 steopenic and osteoporotic patients, whereas bisphosphonates were associated with increased fracture

283 Bisphosphonates were effective in increasing BMD, but no

284 Results Adjuvant bisphosphonates were found to reduce bone recurrence and

285 Participants who had ever used oral bisphosphonates were less likely than non-users to be di

286 were each reported by over 15% of women, and bisphosphonates were reported by 4.5%.

287 Considering low bioavailability of bisphosphonates when administered orally, subsequent stu

288 Zoledronic acid (ZOL) is a third generation bisphosphonate which can be used as a drug for the treat

289 osis has been antiresorptive agents (such as bisphosphonates), which have been effective with continu

290 e pathways influenced by nitrogen-containing bisphosphonates, which are associated with improved surv

291 also include the administration of drugs as bisphosphonates, which reduce the formation of circulati

292 an orally and intravenously available amino-bisphosphonate with a favorable toxicity profile.

293 Although the design of novel bisphosphonates with improved physicochemical properties

294 sed controlled trials combining docetaxel or bisphosphonates with standard of care in hormone-sensiti

295 The inhibitory capacity of bisphosphonates, with mechanistic implications, was conf

296 s 0 to 2 and clinical decision to treat with bisphosphonates within 3 months of randomisation were ra

297 The potent nitrogen-containing bisphosphonate zoledronate inhibits farnesyl pyrophospha

298 in Sprague Dawley rats (n = 30), and either bisphosphonate (zoledronate [Zol]), PTH, or saline (vehi

299 These agents are the bisphosphonate zoledronic acid and the monoclonal antibo

300 ethyl-glutaryl (HMG)-CoA reductase and the N-bisphosphonate zoledronic acid monohydrate, an inhibitor